BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Income Statement
NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 11.69M | 21.44M | 24.82M | 24.54M | 31.68M | |||
| Research and Development | 4.65M | 10.75M | 13.96M | 15.24M | 22.33M | |||
| Selling, General, and Administrative Expenses | 7.04M | 10.69M | 10.87M | 9.30M | 9.36M | |||
| Operating Income | -11.69M | -21.44M | -24.82M | -24.54M | -31.68M | |||
| Interest Income/Expense | 147.00K | 4.69M | N/A | N/A | N/A | |||
| Other Income/Expense | -77.00K | -447.00K | 550.00K | 80.00K | -130.00K | |||
| Income Before Taxes | -11.62M | -17.19M | -24.28M | -24.46M | -31.81M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -11.62M | -17.19M | -24.28M | -24.46M | -31.81M | |||
| EBITDA | -11.45M | -21.17M | -24.53M | -24.28M | -31.46M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.31 | -5.99 | -0.66 | -0.68 | -1.07 | |||
| Non GAAP EPS | -2.37 | N/A | -9.90 | -10.20 | -16.20 | |||
| Statistics | ||||||||
All data in USD